# GI Innovation

Source: https://onco.cc/companies/gi-innovation/  
OnCo record `gi-innovation` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GI Innovation is a South Korea-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific fusion proteins GI-101, GI-102 and GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma.

## Summary

GI Innovation is a South Korean biotechnology company developing bispecific fusion protein drugs on its GI-SMART platform for immuno-oncology and allergy. Its lead cancer candidates are GI-101 and GI-102 (CD80 and IL-2 variant fusion proteins) and GI-108 (anti-CD73 with an IL-2 variant), in phase 1/2 trials in Korea, the United States and Australia. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07172802 (phase 1/2, A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy...), NCT05824975 (phase 1/2, A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and...) and NCT04977453 (phase 1/2, GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: GI Innovation, Inc.
- Tags: ctgov-sponsor
- HQ: Seoul
- Type: biotech
- Website: https://www.gi-innovation.com
- Ticker: KOSDAQ:358570

## Sources

- Official website: https://www.gi-innovation.com
- ClinicalTrials.gov: trials led by GI Innovation: https://clinicaltrials.gov/search?lead=GI%20Innovation%2C%20Inc.

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Eribulin](https://onco.cc/drugs/eribulin/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- trials: [A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07172802/), [A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu](https://onco.cc/trials/nct05824975/), [GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors](https://onco.cc/trials/nct04977453/)

---
JSON: https://onco.cc/api/v1/entities/gi-innovation.json